Trials / Active Not Recruiting
Active Not RecruitingNCT06372457
COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
mavaCamten ObservationaL evIdence Global cOnsortium in HCM (COLLIGO-HCM)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy (HCM) treatment in real-world clinical practice.
Detailed description
The mavaCamten ObservationaL evIdence Global cOnsortium in hypertrophic cardiomyopathy (COLLIGO-HCM) is a global observational research initiative aiming to describe the real-world outcomes of treatments for obstructive hypertrophic cardiomyopathy (HCM), including mavacamten. This retrospective study uses data from existing medical records and electronic registries from HCM centers around the world.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Approved Hypertrophic Cardiomyopathy drug treatments | As per product label |
| DRUG | Mavacamten | As per product label |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2025-03-01
- Completion
- 2025-06-15
- First posted
- 2024-04-18
- Last updated
- 2024-04-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06372457. Inclusion in this directory is not an endorsement.